Asia Pacific Infectious Disease Diagnosis & Treatment Market Research Report, By Applications (AIDS, Tuberculosis (TB), Hepatitis, HPV, And Others), By Treatment (Antibiotics, Antivirals, Antifungals, Anti-Parasitic, Alternative Medicine And Others), By Diagnostic Techniques (Immunoassays, PCR, Cell Cultures And Other), By End Users (Hospitals, Clinics, Reference Labs And Others)- Forecast Till 2032

Asia Pacific Infectious Disease Diagnosis & Treatment Market Overview

The APAC Infectious Disease Diagnosis & Treatment market is anticipated to reach USD 3.1 Billion by 2032 at a CAGR 2.9% during the forecast period 2023-2032.

The APAC infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The APAC  infectious illness diagnosis and treatment market value was estimated at around USD 179.58 Billion in the year 2018. APAC infectious disease diagnosis & treatment market is expected to grow at a CAGR (Compound Annual Growth Rate) of about 7.84% in the coming years.

Bacteria, viruses, fungi, and parasites are all responsible for infectious disorders. These illnesses can be spread by insects, animals, contaminated food or drink, or exposure to an infected environment. The market is predicted to escalate due to the rising incidence of infectious illnesses and increased awareness of these diseases. According to a World Health Organization (WHO) report, almost 50,000 people die every day due to infectious diseases.

In February 2024, at MWC Barcelona Huawei officially unveiled its Medical Technology Digitalization Solution as part of spearheading the healthcare industry’s digital and intelligent Upgrade. This focuses on pathology and medical imaging. These include SmartCache intelligent pre-reading, improving image reading efficiency and achieving zero latency during data retrieval; Huawei-developed compression algorithm saving up to %30 storage and %70 cabinet space; and video-network synergy offering consistent remote diagnosis for promoting hierarchical diagnosis and treatment.

SymphonyAI, a leading provider of predictive and generative enterprise AI SaaS solutions, announced SensaAI for sanctions, which is available now as a “platform agnostic AI upgrade” for any sanction’s solution in APAC at Money20/20 Asia held in April this year. It dramatically impacts sanctions evasion efforts via optimizers' match accuracy using deep context-aware AI-based matching algorithms. Delivered through an API (application programming interface), SensaAI for sanctions is pre-trained, so ready to go out of the box. Leveraging the organization’s current data, SensaAI for sanctions functions in tandem with AI-powered rules-based systems that drive the match process from rationalizing unstructured data containing SWIFT transaction data.

In April 2023, EliTech plans to introduce EliVerse-an automated high throughput molecular diagnostics instrument into European market by 2024.

In April 2023, Cepheid announced its plan to develop new tests for various infectious diseases such as tuberculosis and respiratory diseases among others in year 2023; this company is one of Danaher’s subsidiaries.

For instance, ELITechGroup outlined their forthcoming high throughput sample-to-result molecular diagnostics instrument in April 2023.

In February 2023,Thermo Fisher Scientific Inc joined forces with MyLab in purchasing RT-PCR kits used for diagnosing various infectious diseases like tuberculosis & HIV. Attraction for more consumers has been made by self-testing kits for HIV infections.

Thermo Fisher Scientific Inc. launched its CE – IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit in January 2023. This move strengthens therapeutic efficacy, encourages viral resistance monitoring, and advances infectious disease market innovation

In July 2022, Roche launched Elecsys HCV Duo, an immunoassay that enables independent and simultaneous determination of hepatitis C virus (HCBv) antigen and antibody status from a single human plasma or serum sample. This discovery improves diagnostic efficiency, streamlines patient management and further enhances the handling of infections diseases that would ultimately push the growth of the market.

In May 2022 The U.S. Food and Drug Administration (FDA) has granted Abbott emergency use authorisation (EUA) for its fastest available molecular point-of-care test which detects new corona virus(COVID-19) results in positive within five minutes and negatives in thirteen minutes.

In May 2022 Quidel Corporation has announced its acquisition of Ortho Clinical Diagnostics as well as other affiliated business groups being a US-based company offering rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems.

Torus Biosystems disclosed series A financing of USD 25 million to propel improved healthcare settings infectious disease diagnostics during May 2022.

Covid-19 Analysis

With the rise of the Covid-19 impact, many large-scale businesses and industries suffered, except healthcare and life support products. The lockdown and physical distancing protocols have affected millions of small and big business institutions alike. The infectious illnesses diagnosis & treatment market saw a slight downfall due to the lockdown and physical distancing.

However, the key companies have adopted measures to expand the distribution of infectious illnesses treatment and diagnosis equipment across the globe. Moreover, people are growing aware of infectious diseases, and the price of pharmaceutical products is increasing. Hence, these factors are expected to boost the APAC infectious disease diagnosis & treatment market value in the years to come.

Asia Pacific Infectious Disease Diagnosis & Treatment Market Trends

Drivers

Infectious illness prevalence in both established and emerging nations would boost the APAC infectious disease diagnosis & treatment market growth. The rising number of prescriptions for infectious illness diagnostic tests is due to diagnosing and managing such disorders. Over the forecast period, these factors, together with the increasing tendency toward preventative care, are projected to increase demand for APAC infectious disease diagnosis & treatment market.

Opportunities 

Due to multiple major and minor significant players, the infectious illnesses treatment & diagnosis market seems fragmented. These market participants attempt to acquire a competitive edge through strategic initiatives such as partnership, acquisition, expansion, cooperation, and product and technology launches. Significant efforts are being made in R&D to produce unique diagnoses & treatment options.

Restraints 

A few factors may inhibit the growth of the APAC infectious disease diagnosis & treatment market share. The development of the infectious illness treatment market is likely to be hampered by stringent government restrictions and a lack of information about treatment choices in developing nations. Inadequate reimbursement is a key stumbling block to the infectious disease diagnostics market's development.

Challenges 

There are various concerns with the market that may challenge the key players of the APAC infectious disease diagnosis & treatment market. This includes the cost of the diagnosis and treatment solutions. High treatment and maintenance costs for infectious diseases and a lack of infrastructure in medium and low-income nations may limit the expansion of the market. Most diagnostic companies have a significant challenge in commercializing their tests, convincing their health insurance to pay for them.

Cumulative Growth Analysis

The APAC infectious disease diagnosis & treatment market is anticipated to grow substantially in the years to come. The infectious illness market value was estimated at around USD 179.58 Billion in 2018 and is expected to grow at a CAGR of about 7.84% in the coming years.

Value Chain Analysis

During the APAC infectious disease diagnosis & treatment market forecast, demand for diagnostics is likely to be driven by the expanding trend of preventive medicine. To strengthen Covid-19 preventive and control efforts, large-scale population-based testing is necessary. Infectious illness diagnostics performs these tests. Hence, it is likely to have a favorable influence on APAC infectious disease diagnosis & treatment market.

Developing economies such as India, South Korea, Brazil, and Mexico will likely provide significant infectious illness diagnostics market participants with new growth prospects. The high illness incidence, big patient population, better healthcare infrastructure, increasing disposable money, and growing medical tourism in these nations contribute to this. Aside from the aforementioned characteristics, the Asia Pacific region has grown as a flexible and business-friendly center due to less strict rules and data requirements.

Asia Pacific Infectious Disease Diagnosis & Treatment Market Segmentation

The global APAC infectious disease diagnosis & treatment market is classified into many segments such as disease types, treatment, and end-user. Listed below are the infectious illness treatment & diagnosis market segments:

Disease Type Outlook

• Bacterial diseases


• Viral diseases


• Fungal diseases


• Parasitic diseases


• Others

Treatment Outlook

• Antibiotics


• Antivirals


• Antifungals


• Anti-parasitic


• Others

End-user Outlook

• Hospitals & clinics


• Ambulatory Care Centers


• Others

Regional Analysis

The regional division of the APAC infectious disease diagnosis & treatment market analysis comprises North America, Europe, Asia Pacific, and the rest of the world. The Americas are expected to dominate the infectious disease treatment market due to a rising patient population suffering from different kinds of infectious illnesses and a growing number of government efforts to prevent contagious diseases in the area.

Due to rising awareness and an increasing patient population suffering from severe infectious diseases, Europe is expected to hold the second-largest position in the APAC  infectious disease diagnosis & treatment market. According to the WHO, 14 million people in Europe are infected with hepatitis C as of 2018. Due to the huge patient population suffering from bacterial infectious illnesses and the increasing number of activities conducted by governments and private organizations to raise awareness about infectious diseases, Asia-Pacific is predicted to be the fastest-growing regional market.

According to a May 2018 study released by the National Center for Biotechnology Information (NCBI), meningitis and pneumonia account for roughly 22% of mortality among children under five in India. Because of the expanding patient population suffering from various infectious illnesses, the APAC infectious disease diagnosis & treatment market in the Middle East and Africa is predicted to rise slowly.

Competitive Landscape 

The companies account for the market profits by adopting various APAC infectious disease diagnosis & treatment market trends such as joint ventures, product launches, company expansions, and procurements. They provide innovative solutions for patients suffering from infectious illnesses.

Key Players

Below are the key companies that offer infectious illness diagnosis and treatment solutions in the global APAC infectious disease diagnosis & treatment market, along with the location of their headquarters:

• Pfizer Inc. (US)


• Bristol-Myers Squibb Company (US)


• Janssen Global Services LLC (US)


• Eli Lilly and Company (US)


• Ortho Clinical Diagnostics (US)


• Merck & Co. Inc. (US)


• AbbVie Inc. (US)


• Hoffmann-La Roche Ltd (Switzerland)


• Novartis AG (Switzerland)


• Aurobindo Pharma (India)


• Bayer AG (Germany)


• Reddy's Laboratories (India)


• Sanofi (France)


• Cipla Inc. (India)


• Seegene Inc. (South Korea)


• ABACUS Diagnostica Oy (Finland)


• GlaxoSmithKline PLC (UK)


• Alkem Labs (India)


• Astellas Pharma Inc. (Japan)